FibroBiologics (FBLG) Operating Income (2023 - 2026)
FibroBiologics (FBLG) posted quarterly Operating Income of -$4.0 million for Q2 2026, up 10.18% year-over-year from -$3.7 million in Q2 2025, and up 20.42% on a QoQ basis from -$5.1 million in Q1 2026.
FibroBiologics (FBLG) Operating Income (2023 - 2026) Analysis & Trends
FibroBiologics has reported Operating Income for 4 years, with the latest figure at -$4.0 million in Q2 2026.
- Operating Income for Q2 2026 came in at -$4.0 million, up 10.18% year-over-year; the trailing twelve-month figure through Jun 2026 was -$16.7 million (down 4.0% YoY), and the FY2025 annual result was -$16.6 million, down 21.2% from the prior year.
- Operating Income advanced to -$4.0 million in Q2 2026, from -$5.1 million in the prior quarter.
- Over five years, Operating Income peaked at -$2.1 million in Q3 2023 and troughed at -$5.1 million in Q1 2026.
- A 4-year average of -$3.5 million and a median of -$3.4 million in 2024 frame the typical range for Operating Income.
- The widest annual swing landed in 2024, when Operating Income plunged 63.35%; it then soared 30.23% in 2025.
- A 4-year view of Operating Income shows it stood at -$2.5 million in 2023, then tumbled by 49.68% to -$3.7 million in 2024, then soared by 30.23% to -$2.6 million in 2025, then slumped by 55.71% to -$4.0 million in 2026.
- Per Business Quant data, the three most recent Operating Income figures were -$4.0 million in Q2 2026, -$5.1 million in Q1 2026, and -$2.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | FibroBiologics | 8.15 Mn | 8.15 Mn | - | -4.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.03 Mn |
| Mar 31, 2026 | -5.07 Mn |
| Dec 31, 2025 | -2.59 Mn |
| Sep 30, 2025 | -5.04 Mn |
| Jun 30, 2025 | -4.49 Mn |
| Mar 31, 2025 | -4.53 Mn |
| Dec 31, 2024 | -3.71 Mn |
| Sep 30, 2024 | -3.35 Mn |
| Jun 30, 2024 | -3.22 Mn |
| Mar 31, 2024 | -3.45 Mn |
| Dec 31, 2023 | -2.48 Mn |
| Sep 30, 2023 | -2.05 Mn |
| Jun 30, 2023 | -2.09 Mn |
| Mar 31, 2023 | -2.27 Mn |